^aBased on derived data which includes protocol deviations.

Note: Dashed line at 0.50 represents median PFS for all patients.

^aMedian PFS is from Kaplan-Meier analysis. CI for median was computed using the Brookmeyer-Crowley method; ^bHazard ratio is from unstratified Cox proportional hazards model with treatment as the only covariate; ^cDisease burden was defined by the number of metastatic disease sites at baseline (low = 0-2; high = 3+). At baseline, 69.8% of patients had liver metastases; ^dRapid progressor status was defined as disease progression within 6 months of concluding a prior course of chemotherapy in early BC; ^eDefined as prior anticancer therapy of ‘anthracyclines,’ ‘doxorubicin,’ ‘epirubicin,’ ‘daunorubicin,’ or ‘idarubicin’ in CMDECOD and CMTRT in ADCM.

^aSubgroup analyses presented only if at least 10 observations in each group; ^bDisease burden was defined by the number of metastatic disease sites at baseline (low = 0-2; high = 3+). At baseline, 69.8% of patients had liver metastases; ^cRapid progressor status was defined as disease progression within 6 months of concluding a prior course of chemotherapy in early BC; ^dAmong patients with rapid progression, 18 were HR+ and 4 were HR-; ^eDefined as prior anticancer therapy of 'anthracyclines,' 'doxorubicin,' 'epirubicin,' 'daunorubicin,' or 'idarubicin' in CMDECOD and CMTRT in ADCM.